Comparing Tumor Treating Fields With and Without FET-PET-Guided Stereotactic Radiosurgery for Adults With Recurrent IDH-Wildtype Glioblastoma
Led by Prof. Franciszek Lukaszczyk Memorial Oncology Center · Updated on 2026-06-25
92
Participants Needed
1
Research Sites
104 weeks
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating whether adding FET-PET-guided stereotactic radiosurgery SRS to Tumor Treating Fields TTFields therapy improves survival in adults with recurrent IDH-wildtype glioblastoma. This brain tumor has limited treatment options and a poor outlook. The study is a prospective randomized trial comparing combined treatment with TTFields alone to determine if survival at one year improves.
Participants are randomly assigned to receive either TTFields plus FET-PET-guided SRS or TTFields alone. TTFields treatment is delivered continuously through scalp-placed transducer arrays for four months. For those in the combined group, stereotactic radiosurgery is performed within 14 days after starting TTFields, targeting tumor areas based on MRI and FET-PET imaging to improve treatment precision.
During the study, participants undergo assessments including survival monitoring up to one year and other outcomes such as progression-free survival, response rates, and treatment-related side effects. Researchers collect imaging and molecular data to evaluate treatment effects and safety. The total participation lasts several months with follow-up for survival and tumor progression.
CONDITIONS
Brief Title
TTFields Plus FET-PET-Guided Stereotactic Radiosurgery Versus TTFields Alone for Recurrent Glioblastoma (Tarrget 2.0)
Research Team
A
Agnieszka Rydzewska, Study Coordinator
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match. Sign up to get personalized trial recommendations delivered to your inbox.
At least six months since previous radiotherapy completion
Contrast-enhancing recurrent lesion visible on MRI
Maximum recurrent lesion diameter of 5 cm or less
Available molecular profile including IDH and MGMT status
Adequate blood, kidney, and liver function
Signed informed consent
You will not qualify if you...
Previous treatment with bevacizumab
Planned chemotherapy or targeted therapy after study intervention
Previous stereotactic re-irradiation in the planned treatment area
More than three tumor recurrences
Significant psychiatric disorders
Significant neurological diseases unrelated to glioblastoma
Implanted pacemaker, defibrillator, deep brain stimulator, or incompatible electronic device
Pregnancy or breastfeeding
Active bleeding inside the brain
Uncontrolled high blood pressure
Severe kidney dysfunction
Participation in another interventional study that may interfere
Your Study Journey
Screening
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Treatment
Duration - 4 months
Participants receive Tumor Treating Fields therapy continuously for four months. Those in the combined group also receive FET-PET-guided stereotactic radiosurgery within 14 days after starting TTFields.
Regular visits during treatment
Follow-up
Duration - Up to 12 months
Participants are monitored for survival, tumor progression, treatment response, and side effects for up to one year after randomization.
Periodic visits and imaging assessments
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Similar Trials
Phase 01 Study Evaluating BDTX-1535 Safety and CNS Penetration in High-Grade Glioma and Glioblastoma with EGFR Alterations Undergoing Tumor Resection
Open-Label Phase 1 Study of Oral GLIX1 for Adults with Recurrent or Progressive High-Grade Glioma
Phase 2 Study of Sitagliptin Treatment in Adults With Progressive Grade 4 Gliomas to Improve Immune Response
Phase 12 Study of Ivonescimab Infusion Treatment for Adults with Recurrent Glioblastoma
Study Comparing Avastin Bevacizumab With or Without NaviFUS Ultrasound System in Adults With Recurrent Glioblastoma Multiforme
Window Studies in Glioblastoma A Phase I Trial Investigating Neoadjuvant Ipilimumab in Newly Diagnosed Glioblastoma
Phase 1 Study of Oral Abexinostat PCI-24781 with Metronomic Temozolomide in Adults with Recurrent High Grade Glioma
Evaluation of Safety, Tolerability, and Preliminary Efficacy of Intravenous VRT106 in Adults With Recurrent or Progressive Glioblastoma
Study of Zedoresertib with Temozolomide, with or without Radiotherapy, in Adults with Glioblastoma or Astrocytoma
Study to Understand Molecular, Immune, and Metabolic Mechanisms in Glioblastoma Progression and Recurrence to Find New Treatments
Have more questions? Get in touch with our team for quick support
Published Research Related To This Trial
Effect of Tumor-Treating Fields Plus Maintenance Temozolomide vs Maintenance Temozolomide Alone on Survival in Patients With Glioblastoma: A Randomized Clinical Trial.
Response Assessment in Neuro-Oncology working group and European Association for Neuro-Oncology recommendations for the clinical use of PET imaging in gliomas.
Nathalie L Albert, Michael Weller, Bogdana Suchorska...